annual meeting program - American Society of Clinical Oncology

3:00 PM - 6:00 PM
ORAL ABSTRACT SESSION
Central Nervous System Tumors
Location: S100b
CME credit: 3
Track(s): Central Nervous System Tumors
Saturday, June 5, 2010
John Frederick De Groot, MD—Co-Chair
University of Texas M. D. Anderson Cancer Center
Myrna Rachel Rosenfeld, MD, PhD—Co-Chair
University of Pennsylvania
3:00 PM NOA-08 randomized phase III trial of 1-week-on/1-week-off temozolomide
versus involved-field radiotherapy in elderly (older than age 65) patients with
newly diagnosed anaplastic astrocytoma or glioblastoma (Methusalem).
(Abstract #LBA2001)
W. Wick, C. Engel, S. E. Combs, G. Nikkhah, J. Steinbach, R. Kortmann,
M. Simon, C. Wille, G. Reifenberger, M. Weller
3:15 PM Glioblastoma (GBM) in elderly patients: A randomized phase III trial
comparing survival in patients treated with 6-week radiotherapy (RT) versus
hypofractionated RT over 2 weeks versus temozolomide single-agent
chemotherapy (TMZ). (Abstract #LBA2002)
A. Malmstrom, B. H. Grønberg, R. Stupp, C. Marosi, D. Frappaz, H. P. Schultz,
M. U. Abacioglu, S. Kinhult, R. Henriksson
Discussion
3:30 PM Stuart Grossman, MD (Abstracts #LBA2001–LBA2002)
The Johns Hopkins University
3:45 PM Efficacy of tailored treatment for high- and low-risk medulloblastoma in
adults: A large prospective phase II trial. (Abstract #2003)
A. A. Brandes, E. Franceschi, A. Tosoni, G. Frezza, R. Agati, A. Maestri,
C. Ghimenton, V. Mazzocchi, L. Scopece, M. Ermani
4:00 PM Everolimus for subependymal giant-cell astrocytomas (SEGAs) in tuberous
sclerosis (TS). (Abstract #2004)
D. N. Franz, D. A. Krueger, M. M. Care, K. Holland-Bouley, K. Agricola, C. Tudor,
P. Mangeshkar, A. W. Byars, T. Sahmoud
4:15 PM Phase II study of preirradiation chemotherapy for CNS germ cell
malignancies: Long-term complications. (Abstract #2005)
S. I. Robinson, J. C. Buckner, C. Raffel, J. E. Hammack, B. W. Scheithauer,
W. Wu, E. G. Shaw
Discussion
4:30 PM To be determined
4:45 PM Phase II study of XL184 (BMS 907351), an inhibitor of MET, VEGFR2, and
RET, in patients (pts) with progressive glioblastoma (GB). (Abstract #2006)
P. Y. Wen, M. Prados, D. Schiff, D. A. Reardon, T. Cloughesy, T. Mikkelsen,
T. Batchelor, J. Drappatz, M. C. Chamberlain, J. F. De Groot
5:00 PM A prospective, randomized, open-label, phase III clinical trial of NovoTTF-
100A versus best standard of care chemotherapy in patients with recurrent
glioblastoma. (Abstract #LBA2007)
R. Stupp, A. Kanner, H. Engelhard, V. Heidecke, S. Tallibert, F. S. Lieberman,
V. Dbaly´, E. D. Kirson, Y. Palti, P. H. Gutin
5:15 PM Updated safety and survival of patients with relapsed glioblastoma treated
with bevacizumab in the BRAIN study. (Abstract #2008)
T. Cloughesy, J. J. Vredenburgh, B. Day, A. Das, H. S. Friedman, for the BRAIN
Investigators
Discussion
5:30 PM Alba Ariela Brandes, MD (Abstracts #2006–2008)
ASL Bologna
181
SATURDAY